Results 131 to 140 of about 721 (146)

Anti-Inflammatory Effects of Varespladib Methyl in Diabetic Patients with Acute Coronary Syndrome

Cardiovascular Drugs and Therapy, 2011
Secretory phospholipase A(2) group IIA (sPLA(2-)IIA) concentration and activity are associated with increased risk of cardiovascular events in acute coronary syndrome (ACS) patients. This study evaluated baseline differences in sPLA(2)-IIA concentration and other inflammatory markers in ACS patients with and without diabetes, and the inflammatory ...
Robert S, Rosenson, Heather, Fraser, Michael A, Goulder, Colin, Hislop   +3 more
openaire   +2 more sources

Ability of the phospholipase A2 inhibitor Varespladib to abrogate or delay lethality induced by neurotoxic snake venoms

Toxicon, 2020
This study investigated the ability of the phospholipase A2 (PLA2) inhibitor Varespladib (LY315920) and its oral prodrug, methyl-Varespladib (LY333013), to abrogate or delay the lethality induced by potent neurotoxic snake venoms in a mouse model. The venoms tested were from Oxyuranus scutellatus, Notechis scutatus, Bungarus multicinctus, and Crotalus ...
Gutiérrez, José María, Lewin, Matthew, Williams, David, Lomonte, Bruno   +3 more
openaire   +1 more source

Snake venom protection by a cocktail of varespladib and broadly neutralizing human antibodies

Cell
Snake envenomation is a neglected tropical disease, with 600 species causing over 100,000 deaths and 300,000 permanent disabilities in humans annually. Broadly neutralizing antibodies and broad chemical inhibitors have been proposed as solutions, but how to develop a therapeutically effective cocktail and the number of required components have been ...
Jacob, Glanville, Mark, Bellin, Sergei, Pletnev, Baoshan, Zhang, Joel Christian, Andrade, Sangil, Kim, David, Tsao, Raffaello, Verardi, Rishi, Bedi, Sindy, Liao, Raymond, Newland, Nicholas L, Bayless, Sawsan, Youssef, Ena S, Tully, Tatsiana, Bylund, Sujeong, Kim, Hannah, Hirou, Tracy, Liu, Peter D, Kwong   +18 more
openaire   +2 more sources

Varespladib (A-002), a Secretory Phospholipase A2 Inhibitor, Reduces Atherosclerosis and Aneurysm Formation in ApoE− / − Mice

Journal of Cardiovascular Pharmacology, 2009
The family of secretory phospholipase A2 (sPLA2) enzymes has been associated with inflammatory diseases and tissue injury including atherosclerosis. A-001 is a novel inhibitor of sPLA2 enzymes discovered by structure-based drug design, and A-002 is the orally bioavailable prodrug currently in clinical development.
Heather, Fraser, Colin, Hislop, Robert M, Christie, Heather L, Rick, Charles A, Reidy, Michael L, Chouinard, Patrick I, Eacho, Kenneth E, Gould, Joaquim, Trias   +8 more
openaire   +2 more sources

Varespladib (LY315920) inhibits neuromuscular blockade induced by Oxyuranus scutellatus venom in a nerve-muscle preparation

Toxicon, 2020
The phospholipase A2 (PLA2) inhibitors varespladib (LY315920) and its orally available derivative methyl-varespladib (LY333013) have been proposed as potential therapies for the treatment of snakebite envenomings in which toxicity depends on the action of PLA2s.
Isadora Caruso, Fontana Oliveira, José María, Gutiérrez, Matthew R, Lewin, Yoko, Oshima-Franco   +3 more
openaire   +2 more sources

Varespladib methyl, an oral phospholipase A2 inhibitor for the potential treatment of coronary artery disease.

IDrugs : the investigational drugs journal, 2009
Varespladib methyl is an oral secretory phospholipase A2 inhibitor that is being developed by Anthera Pharmaceuticals Inc for the potential treatment of coronary artery disease, acute coronary syndrome and inflammation. Varespladib methyl is a prodrug that is rapidly metabolized to varespladib, and both compounds are able to potently inhibit the ...
Mahir, Karakas, Wolfgang, Koenig
openaire   +1 more source

Adverse Effects Associated with Varespladib in the VISTA-16 Trial

MD Conference Express, 2013
M. Cunningham, S. J. Nicholls
openaire   +1 more source

4 Oral Varespladib for Snakebite Envenoming: The BRAVO International Randomized Controlled Trial

Annals of Emergency Medicine, 2023
C. Gerardo, T. Platts-Mills, S. Samuel, S. Kumar, F. Shirazi, S. Kotehal, P. Akpunonu, P. Mukherjee, R. Carter, M. Lewin   +9 more
openaire   +1 more source

Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib

Toxins, 2021
Jeroen Kool, Taline Kazandjian, Nicholas Casewell   +2 more
exaly  

Varespladib trial terminated, increased MI risk

Reactions Weekly, 2014
openaire   +1 more source